CoRLEIT, Covid Regional Lung EIT

CoRLEIT、Covid 区域肺 EIT

基本信息

批准号：
EP/V044036/1
负责人：
Richard Bayford
金额：
$ 68.43万
依托单位：
Middlesex University
依托单位国家：
英国
项目类别：
Research Grant
财政年份：
2020
资助国家：
英国
起止时间：
2020 至无数据
项目状态：
已结题

来源：
https://gtr.ukri.org/projects?ref=EP%2FV044036%2F1
关键词：
CoRLEIT Covid Regional Lung EIT

项目摘要

A key challenge for the COVID-19 pandemic is the requirement to monitor for deterioration and provide timely escalation interventions to an unprecedented number of patients at risk of respiratory failure. Existing monitoring poorly predicts sudden deterioration in COVID-19pneumonia. Regional information, currently from CT scans, has been informative (Scudellari, 2020) [1], but does not provide dynamic information. There is an urgent need for a low cost, bedside,non-invasive imaging system, to continuously monitor dynamic changes in regional lung ventilation [2][3][4][5].Electrical Impedance Tomography (EIT) can provide this and has proved useful in managing acute respiratory syndrome in infants and adults (Bachmann et al 2018) [2]. We have already developeda low cost wearable EIT system for neonates (CRADL; http://cradlproject.org/) and obtainedclinical results from 200 subjects, each for up to 72 hours of continuous monitoring of temporal lung volume changes.This technology can be repurposed for COVID-19 patients (Appendix) with the aim of providing novel insights into COVID-19 pathophysiology, and with the potential to provide a solution for respiratory failure monitoring at scale. Using EIT in HDU-pre-ICU patients, evaluating and stratifying treatment response (to prone positioning, CPAP, other breathing support) and thenfollowing through into ICU with ventilation interventions if they deteriorate, will add invaluable information about how COVID-19 effects the respiratory system. This will establish the merits of EIT monitoring for COVID-19 respiratory failure, in particular enhance and expedite clinical research into optimal COVID-19 breathing support treatment strategy and facilitate development of EIT guided personalised treatment plans.

COVID-19大流行的一个主要挑战是监测恶化并及时升级干预措施，以使前所未有的患者有呼吸衰竭的风险。现有的监测很差预测Covid-19pneumonia的突然恶化。目前来自CT扫描的区域信息已提供信息（Scudellari，2020）[1]，但没有提供动态信息。迫切需要低成本，床旁，非侵入性成像系统，以不断监控区域肺通风的动态变化[2] [3] [4] [4] [5] .electrical Pressance阻抗层析成像（EIT）可以提供此功能，并证明可用于管理婴儿和成人的急性呼吸综合症（Bachmann等）（Bachmann et al 2018）[2] [2] [2]。 We have already developeda low cost wearable EIT system for neonates (CRADL; http://cradlproject.org/) and obtainedclinical results from 200 subjects, each for up to 72 hours of continuous monitoring of temporal lung volume changes.This technology can be repurposed for COVID-19 patients (Appendix) with the aim of providing novel insights into COVID-19 pathophysiology, and with the potential提供大规模监测呼吸衰竭监测的解决方案。在HDU-PRE-ICU患者中使用EIT，评估和分层的治疗反应（易于定位，CPAP，其他呼吸支持），然后在通风干预措施下进行ICU，如果他们恶化，将添加有关COVID-19的无价信息。这将确定EIT监测于19 Covid-19的呼吸衰竭的优点，特别是增强并加快了临床研究，以最佳的COVID-19呼吸支持治疗策略，并促进EIT指导的个性化治疗计划的制定。